220 related articles for article (PubMed ID: 25861217)
1. GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.
Zhao Y; Polley EC; Li MC; Lih CJ; Palmisano A; Sims DJ; Rubinstein LV; Conley BA; Chen AP; Williams PM; Kummar S; Doroshow JH; Simon RM
Cancer Inform; 2015; 14(Suppl 2):45-55. PubMed ID: 25861217
[TBL] [Abstract][Full Text] [Related]
2. OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials.
Palmisano A; Zhao Y; Li MC; Polley EC; Simon RM
Brief Bioinform; 2017 Sep; 18(5):723-734. PubMed ID: 27422621
[TBL] [Abstract][Full Text] [Related]
3. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.
Lih CJ; Sims DJ; Harrington RD; Polley EC; Zhao Y; Mehaffey MG; Forbes TD; Das B; Walsh WD; Datta V; Harper KN; Bouk CH; Rubinstein LV; Simon RM; Conley BA; Chen AP; Kummar S; Doroshow JH; Williams PM
J Mol Diagn; 2016 Jan; 18(1):51-67. PubMed ID: 26602013
[TBL] [Abstract][Full Text] [Related]
4. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
5. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
6. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
9. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
[TBL] [Abstract][Full Text] [Related]
11. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
[TBL] [Abstract][Full Text] [Related]
12. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
Wakai T; Prasoon P; Hirose Y; Shimada Y; Ichikawa H; Nagahashi M
Int J Clin Oncol; 2019 Feb; 24(2):115-122. PubMed ID: 30515675
[TBL] [Abstract][Full Text] [Related]
14. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
15. Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature.
Tayshetye P; Miller K; Monga D; Brem C; Silverman JF; Finley GG
Front Med (Lausanne); 2020; 7():314. PubMed ID: 32760731
[No Abstract] [Full Text] [Related]
16. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing.
Patel NM; Michelini VV; Snell JM; Balu S; Hoyle AP; Parker JS; Hayward MC; Eberhard DA; Salazar AH; McNeillie P; Xu J; Huettner CS; Koyama T; Utro F; Rhrissorrakrai K; Norel R; Bilal E; Royyuru A; Parida L; Earp HS; Grilley-Olson JE; Hayes DN; Harvey SJ; Sharpless NE; Kim WY
Oncologist; 2018 Feb; 23(2):179-185. PubMed ID: 29158372
[TBL] [Abstract][Full Text] [Related]
18. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
19. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
